Matrix Biomed, Inc.   Report issue

For profit Phase 2
Founded: Irvine CA United States (2018)

Organization Overview

First Clinical Trial
2018
NCT03480971
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Matrix Biomed, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

mbm-01 (1 trial)

tempol (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Mucositis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 2